Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Sales | 13,280,000 | 14,206,000 | 9,478,000 | 14,039,000 | 14,541,000 |
| Cost of Goods | 4,087,000 | 4,606,000 | 2,197,000 | 4,575,000 | 4,610,000 |
| Gross Profit | 9,193,000 | 9,600,000 | 7,281,000 | 9,464,000 | 9,931,000 |
| Operating Expenses | 6,160,000 | 6,704,000 | 4,566,000 | 6,516,000 | 6,823,000 |
| Operating Income | 3,033,000 | 2,896,000 | 2,715,000 | 2,948,000 | 3,108,000 |
| Interest Expense | 175,000 | 175,000 | 199,000 | 178,000 | 183,000 |
| Other Income | 176,000 | 118,000 | 145,000 | 11,000 | 210,000 |
| Pre-tax Income | 3,034,000 | 2,839,000 | 2,661,000 | 2,781,000 | 3,135,000 |
| Income Tax | 447,000 | 417,000 | 492,000 | 364,000 | 460,000 |
| Net Income Continuous | 2,587,000 | 2,422,000 | 2,169,000 | 2,417,000 | 2,675,000 |
| Net Income Discontinuous | -39,000 | N/A | N/A | N/A | N/A |
| Minority Interests | 32,000 | 24,000 | 37,000 | 27,000 | 27,000 |
| Net Income | $2,516,000 | $2,398,000 | $1,985,000 | $2,390,000 | $2,648,000 |
| EPS Basic Total Ops | 1.03 | 0.98 | 0.82 | 0.99 | 1.09 |
| EPS Basic Continuous Ops | 1.04 | 0.99 | 0.90 | 1.00 | 1.10 |
| EPS Basic Discontinuous Ops | -0.01 | N/A | N/A | N/A | N/A |
| EPS Diluted Total Ops | 1.01 | 0.97 | 0.80 | 0.98 | 1.09 |
| EPS Diluted Continuous Ops | 1.03 | 0.98 | 0.88 | 0.99 | 1.10 |
| EPS Diluted Discontinuous Ops | -0.02 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $3,993,000 | $4,090,000 | $2,715,000 | $4,180,000 | $4,302,000 |